0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CLEC3B

CLEC3B

Brief Information

Name:Tenascin
Target Synonym:Glioma-associated-extracellular matrix antigen,GMEM,Neuronectin,Tenascin-C,TN-C,GP 150-225,TNC,Tenascin C,Deafness, Autosomal Dominant 56,Hexabrachion (Tenascin),Myotendinous Antigen,Cytotactin,HXB,JI,TN,Tenascin-C Additional Domain 1,Tenascin-C Isoform 1
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
CLB-H5226 Human Human CLEC3B / Tetranectin Protein, His Tag, low endotoxin
CLB-H5226-structure
CLB-H5226-sds

Synonym Name

CLEC3B,Tetranectin,TN,TNA

Background

C-type lectin domain family 3 member B (CLEC3B) is also known as Tetranectin, Plasminogen kringle 4-binding protein, is a secreted homotrimer. CLEC3B contains 1 C-type lectin domain and mainly found in plasma. Tetranectin / CLEC3B binds to plasminogen and to isolated kringle 4. CLEC3B may be involved in the packaging of molecules destined for exocytosis. Decreased plasma Tetranectin or increased Tetranectin in stroma of cancers correlates with cancer progression and adverse prognosis.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
F16 IL2 fusion protein (Philogen) F-16-IL-2 Phase 2 Clinical Philogen Solid tumours; Carcinoma, Merkel Cell; Hemangiosarcoma; Breast Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung; Melanoma Details

This web search service is supported by Google Inc.

totop